Generics

Orfadin had a global market value of approximately $85 million over the last four quarters, according to Swedish Orphan Biovitrum.

Par is introducing an authorized generic of Merck Sharp & Dohme’s Noxafil (posaconazole) delayed-release tablets, and also plans to launch posaconazole 40mg/mL oral suspension in the coming months.

Elidel cream, 1%, had a market value of roughly $198.8 million, for the 12 months ending July 2019.

Nascobal had a market value of $90 million for the 12 months ending June 2019.

Fresenius Kabi is offering phenylephrine hydrochloride injection in 1-ml, single-dose vials, as well as in 5-ml, and 10-ml bulk packages.

Morphine sulfate tablets had a market value of approximately $49 million for the 12 months ended June 2019, according to IQVIA.

Samsung Bioepis has received approval for Hadlima, which is used for the treatment of rheumatoid arthritis.

Noxafil delayed-release tablets had a market value of approximately $325 million for the 12 months ended June 2019, although actual generic market values are expected to be lower.